Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Cellular Injury V: Apoptosis and Autophagy

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety and Management of Targeted Therapies for Relapsed/Refractory Chronic Lymphocytic Leukemia.

Drug safety·2026

Same author

A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia.

Blood cancer journal·2026

Same author

Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasone.

Haematologica·2026

Same author

Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated With Front-Line Daratumumab Lenalidomide and Dexamethasone.

American journal of hematology·2026

Same author

Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.

Blood advances·2025

Same author

Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience.

Blood cancer journal·2025

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Targeting the Bcl-2.

Mehul P Patel¹, Aisha Masood, Priya S Patel

¹Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.

Current Opinion in Oncology

|September 5, 2009

Summary

Targeting the Bcl-2 (B-cell lymphoma 2) protein is a promising cancer treatment strategy. Novel small molecule inhibitors show potential in restoring apoptosis and improving outcomes, offering new hope for patients.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Related Experiment Videos

Last Updated: Jun 20, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Area of Science:

Oncology
Molecular Biology
Cancer Therapeutics

Background:

The Bcl-2 family regulates apoptosis, a critical process in cancer development.
Bcl-2 overexpression correlates with drug resistance and poor prognosis in cancer patients.
Targeting Bcl-2 aims to restore apoptosis and enhance anti-cancer effects.

Purpose of the Study:

To review clinical data on novel compounds targeting Bcl-2.
To evaluate the therapeutic potential of Bcl-2 inhibitors in cancer treatment.

Main Methods:

Review of clinical trial data for Bcl-2 targeting agents.
Analysis of preclinical and clinical evaluations of Bcl-2 downregulation strategies.

Main Results:

Bcl-2 antisense therapies yielded disappointing clinical results.
New small molecule Bcl-2 inhibitors demonstrate high target affinity and improved safety.
Early clinical trials show promising efficacy of Bcl-2 inhibitors, both as monotherapy and in combination treatments.

Conclusions:

Bcl-2 downregulation remains a key strategy for cancer therapy.
Novel Bcl-2 inhibitors are beginning to fulfill the therapeutic promise of targeting this pathway.